These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 35941342)
1. Natural History and Management of Small-Bowel Obstruction in Patients After Cytoreductive Surgery and Intraperitoneal Chemotherapy. Mor E; Shemla S; Assaf D; Laks S; Benvenisti H; Hazzan D; Shiber M; Shacham-Shmueli E; Margalit O; Halpern N; Boursi B; Beller T; Perelson D; Purim O; Zippel D; Ben-Yaacov A; Nissan A; Adileh M Ann Surg Oncol; 2022 Dec; 29(13):8566-8579. PubMed ID: 35941342 [TBL] [Abstract][Full Text] [Related]
2. Predictors of Small Bowel Obstruction Post-Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Jedrzejko N; Wong A; MacNeill AJ; Hamilton TD J Gastrointest Surg; 2022 Oct; 26(10):2176-2183. PubMed ID: 35852704 [TBL] [Abstract][Full Text] [Related]
3. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy]. Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167 [No Abstract] [Full Text] [Related]
4. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes. Valle SJ; Alzahrani N; Alzahrani S; Traiki TB; Liauw W; Morris DL Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038 [TBL] [Abstract][Full Text] [Related]
5. Factors Associated with Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis. Martin AS; Abbott DE; Hanseman D; Sussman JE; Kenkel A; Greiwe P; Saeed N; Ahmad SH; Sussman JJ; Ahmad SA Ann Surg Oncol; 2016 Jun; 23(6):1941-7. PubMed ID: 26842489 [TBL] [Abstract][Full Text] [Related]
6. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC. van Eden WJ; Kok NFM; Woensdregt K; Huitema ADR; Boot H; Aalbers AGJ Eur J Surg Oncol; 2018 Feb; 44(2):220-227. PubMed ID: 29258720 [TBL] [Abstract][Full Text] [Related]
7. A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. Baumgartner JM; Kwong TG; Ma GL; Messer K; Kelly KJ; Lowy AM Ann Surg Oncol; 2016 May; 23(5):1609-17. PubMed ID: 26678406 [TBL] [Abstract][Full Text] [Related]
8. [Meta analysis of whether cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy can improve survival in patients with colorectal cancer peritoneal metastasis]. Liu D; Wang H; Yuan ZX; Chen WW; Wu ZJ; Liu XX; Luo J; Chu LL; Li Y; Cai J Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):256-263. PubMed ID: 34645170 [No Abstract] [Full Text] [Related]
9. Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Tan GHC; Chia CS; Tan SH; Soo KC; Teo MCC Int J Clin Oncol; 2018 Oct; 23(5):989-998. PubMed ID: 29869757 [TBL] [Abstract][Full Text] [Related]
10. Incidence of leukopenia and thrombocytopenia with cisplatin plus mitomycin-c versus melphalan in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Hakeam HA; Arab A; Azzam A; Alyahya Z; Eldali AM; Amin T Cancer Chemother Pharmacol; 2018 Apr; 81(4):697-704. PubMed ID: 29429054 [TBL] [Abstract][Full Text] [Related]
11. The impact of gastrointestinal anastomotic leaks on survival of patients undergoing cytoreductive surgery and heated intraperitoneal chemotherapy. Mor E; Assaf D; Laks S; Benvenisti H; Ben-Yaacov A; Zohar N; Schtrechman G; Hazzan D; Shacham-Shmueli E; Perelson D; Adileh M; Nissan A Am J Surg; 2022 Feb; 223(2):331-338. PubMed ID: 33832737 [TBL] [Abstract][Full Text] [Related]
12. Palliative Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis: Is It Safe and Effective? Strong EA; Livingston A; Gracz M; Peltier W; Tsai S; Christians K; Gamblin TC; Kersting K; Clarke CN J Surg Res; 2022 Oct; 278():31-38. PubMed ID: 35588572 [TBL] [Abstract][Full Text] [Related]
13. Delayed presentation of major complications in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy following hospital discharge. Bhagwandin SB; Naffouje S; Salti G J Surg Oncol; 2015 Mar; 111(3):324-7. PubMed ID: 25557653 [TBL] [Abstract][Full Text] [Related]
14. Recurrence and Survival Outcomes After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Small Bowel Adenocarcinoma. Saxena A; Valle SJ; Liauw W; Morris DL Anticancer Res; 2017 Oct; 37(10):5737-5742. PubMed ID: 28982894 [TBL] [Abstract][Full Text] [Related]
15. High-grade postoperative complications affect survival outcomes of patients with colorectal Cancer peritoneal metastases treated with Cytoreductive surgery and Hyperthermic Intraperitoneal chemotherapy. Zhou S; Feng Q; Zhang J; Zhou H; Jiang Z; Liu Z; Zheng Z; Chen H; Wang Z; Liang J; Pei W; Liu Q; Zhou Z; Wang X BMC Cancer; 2021 Jan; 21(1):41. PubMed ID: 33413223 [TBL] [Abstract][Full Text] [Related]
16. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504 [TBL] [Abstract][Full Text] [Related]
17. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for small bowel neuroendocrine tumors with peritoneal metastasis. Hajjar R; Mercier F; Passot G; Pasquer A; Gelli M; Levine EA; Villeneuve L; Poncet G; Walter T; Glehen O Eur J Surg Oncol; 2022 Jul; 48(7):1626-1630. PubMed ID: 35418324 [TBL] [Abstract][Full Text] [Related]
18. Desmoplastic Small Round Cell Tumor: Long-Term Complications After Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. Stiles ZE; Murphy AJ; Anghelescu DL; Brown CL; Davidoff AM; Dickson PV; Glazer ES; Bishop MW; Furman WL; Pappo AS; Lucas JT; Deneve JL Ann Surg Oncol; 2020 Jan; 27(1):171-178. PubMed ID: 30963398 [TBL] [Abstract][Full Text] [Related]
19. Splenectomy Increases Postoperative Complications Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Dagbert F; Thievenaz R; Decullier E; Bakrin N; Cotte E; Rousset P; Vaudoyer D; Passot G; Glehen O Ann Surg Oncol; 2016 Jun; 23(6):1980-5. PubMed ID: 26913716 [TBL] [Abstract][Full Text] [Related]
20. Cytoreductive Surgery with HIPEC is a Safe and Effective Palliative Option in Chemorefractory Symptomatic Peritoneal Metastasis. Zhang C; Patel A; Hegeholz D; Brown K; Shostrom V; Pottebaum M; Foster JM Ann Surg Oncol; 2022 May; 29(5):3337-3346. PubMed ID: 35211861 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]